vs
Side-by-side financial comparison of Coherus Oncology, Inc. (CHRS) and i-80 Gold Corp. (IAUX). Click either name above to swap in a different company.
i-80 Gold Corp. is the larger business by last-quarter revenue ($21.3M vs $12.7M, roughly 1.7× Coherus Oncology, Inc.). Coherus Oncology, Inc. runs the higher net margin — -295.3% vs -401.9%, a 106.6% gap on every dollar of revenue.
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
i-80 Gold Corp is a mineral exploration and development firm focused on gold and silver asset operations in Nevada, US. It advances high-potential mining projects, using responsible extraction practices to deliver precious metals to global industrial and investment markets.
CHRS vs IAUX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.7M | $21.3M |
| Net Profit | $-37.6M | $-85.6M |
| Gross Margin | 68.3% | 22.0% |
| Operating Margin | -359.9% | -291.6% |
| Net Margin | -295.3% | -401.9% |
| Revenue YoY | 64.9% | — |
| Net Profit YoY | 25.7% | — |
| EPS (diluted) | $-0.34 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.7M | $21.3M | ||
| Q3 25 | $11.6M | $32.0M | ||
| Q2 25 | $10.3M | $27.8M | ||
| Q1 25 | — | $14.0M | ||
| Q3 24 | — | $11.5M | ||
| Q2 24 | $10.3M | $7.2M | ||
| Q3 23 | $74.6M | — | ||
| Q2 23 | $58.7M | — |
| Q4 25 | $-37.6M | $-85.6M | ||
| Q3 25 | $-35.5M | $-41.9M | ||
| Q2 25 | $297.8M | $-30.2M | ||
| Q1 25 | — | $-41.2M | ||
| Q3 24 | — | $-43.1M | ||
| Q2 24 | $-12.9M | $-41.0M | ||
| Q3 23 | $-39.6M | — | ||
| Q2 23 | $-42.9M | — |
| Q4 25 | 68.3% | 22.0% | ||
| Q3 25 | 67.8% | 9.7% | ||
| Q2 25 | 66.9% | 2.9% | ||
| Q1 25 | — | 20.7% | ||
| Q3 24 | — | -42.7% | ||
| Q2 24 | 82.4% | -171.4% | ||
| Q3 23 | 56.1% | — | ||
| Q2 23 | 57.7% | — |
| Q4 25 | -359.9% | -291.6% | ||
| Q3 25 | -383.1% | -86.7% | ||
| Q2 25 | -443.6% | -67.4% | ||
| Q1 25 | — | -112.3% | ||
| Q3 24 | — | -210.0% | ||
| Q2 24 | -384.9% | -435.2% | ||
| Q3 23 | -42.9% | — | ||
| Q2 23 | -58.8% | — |
| Q4 25 | -295.3% | -401.9% | ||
| Q3 25 | -307.1% | -130.8% | ||
| Q2 25 | 2903.9% | -108.5% | ||
| Q1 25 | — | -293.3% | ||
| Q3 24 | — | -374.5% | ||
| Q2 24 | -125.5% | -570.8% | ||
| Q3 23 | -53.2% | — | ||
| Q2 23 | -73.0% | — |
| Q4 25 | $-0.34 | $-0.10 | ||
| Q3 25 | $-0.31 | $-0.05 | ||
| Q2 25 | $2.57 | $-0.05 | ||
| Q1 25 | — | $-0.10 | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | $-0.11 | $-0.11 | ||
| Q3 23 | $-0.41 | — | ||
| Q2 23 | $-0.49 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.1M | $63.2M |
| Total DebtLower is stronger | — | $174.7M |
| Stockholders' EquityBook value | $61.0M | $346.8M |
| Total Assets | $258.3M | $703.4M |
| Debt / EquityLower = less leverage | — | 0.50× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.1M | $63.2M | ||
| Q3 25 | $191.7M | $102.9M | ||
| Q2 25 | $237.6M | $133.7M | ||
| Q1 25 | — | $13.5M | ||
| Q3 24 | — | $21.8M | ||
| Q2 24 | $159.2M | $47.8M | ||
| Q3 23 | $131.1M | — | ||
| Q2 23 | $144.7M | — |
| Q4 25 | — | $174.7M | ||
| Q3 25 | — | $175.9M | ||
| Q2 25 | — | $175.8M | ||
| Q1 25 | — | $197.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | $61.0M | $346.8M | ||
| Q3 25 | $87.8M | $423.0M | ||
| Q2 25 | $119.8M | $463.5M | ||
| Q1 25 | — | $318.0M | ||
| Q3 24 | — | $346.9M | ||
| Q2 24 | $-84.1M | $377.2M | ||
| Q3 23 | $-133.6M | — | ||
| Q2 23 | $-174.8M | — |
| Q4 25 | $258.3M | $703.4M | ||
| Q3 25 | $516.5M | $756.2M | ||
| Q2 25 | $439.5M | $782.9M | ||
| Q1 25 | — | $659.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | $674.9M | — | ||
| Q3 23 | $583.8M | — | ||
| Q2 23 | $469.6M | — |
| Q4 25 | — | 0.50× | ||
| Q3 25 | — | 0.42× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 0.62× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.7M | $-34.3M |
| Free Cash FlowOCF − Capex | — | $-39.2M |
| FCF MarginFCF / Revenue | — | -184.3% |
| Capex IntensityCapex / Revenue | — | 23.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-93.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-19.7M | $-34.3M | ||
| Q3 25 | $-46.3M | $-15.2M | ||
| Q2 25 | $-46.6M | $-11.3M | ||
| Q1 25 | — | $-22.7M | ||
| Q3 24 | — | $-23.5M | ||
| Q2 24 | $59.7M | $-24.6M | ||
| Q3 23 | $-54.3M | — | ||
| Q2 23 | $-38.9M | — |
| Q4 25 | — | $-39.2M | ||
| Q3 25 | — | $-18.5M | ||
| Q2 25 | — | $-12.4M | ||
| Q1 25 | — | $-23.1M | ||
| Q3 24 | — | $-23.8M | ||
| Q2 24 | — | $-25.1M | ||
| Q3 23 | — | — | ||
| Q2 23 | $-39.0M | — |
| Q4 25 | — | -184.3% | ||
| Q3 25 | — | -57.8% | ||
| Q2 25 | — | -44.7% | ||
| Q1 25 | — | -164.1% | ||
| Q3 24 | — | -206.7% | ||
| Q2 24 | — | -349.1% | ||
| Q3 23 | — | — | ||
| Q2 23 | -66.4% | — |
| Q4 25 | — | 23.1% | ||
| Q3 25 | — | 10.2% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.5% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | — | 7.3% | ||
| Q3 23 | 0.0% | — | ||
| Q2 23 | 0.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
IAUX
| Granite Creek Mining Company | $20.3M | 95% |
| Ruby Hill Mining Company LLC | $991.0K | 5% |
| Lone Tree Minning Company | $3.0K | 0% |
